Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To evaluate the magnetic resonance (MR) imaging findings of breast cancer subtypes based on the profiles of ER/PR and Her2.

Methods: A retrospective study was conducted for 267 breast cancer subjects between February 2007 and January 2011. Clinicopathologic features and MR imaging findings of four subtypes were compared. The Chi-square (χ(2)) test, Fisher's exact test and χ(2) section method were employed for categorical variables.

Results: MR imaging findings:Patients with segment or linear enhancement type accounted for 25.6% in ER/PR(+), Her2(+) subtype group and 36.1% in ER/PR(-), Her2(+) subtype, no significant difference existed between them (χ(2) = 1.112, P = 0.641). But they were significantly higher than ER/PR(+), Her2(-) subtype group and ER/PR(-), Her2(-) subtype group (χ(2) = 32.793, P < 0.001; χ(2) = 14.565, P < 0.001). ER/PR(-), Her2(-) subtype patients accounted for 14.6% of the total breast cancer patients (39/267). Subjects with ER/PR(-), Her2(-) subtype were more likely to present unifocal (91.7%, 33/36) and mass type lesion (92.3%, 36/39). The mass type lesions in ER/PR(-), Her2(-) subtype group were more likely to showed smooth margin [58.3% (21/36), P < 0.001], very high intratumoral signal and peripheral hyperintense pattern on fat suppression T2-weighted imaging (P < 0.001) and early rim enhancement [81.5% (29/36), P < 0.001]. No significantly difference of four subtypes were found on number of mass, mass shape and pattern at dynamic enhancement imaging (χ(2) = 1.413, P = 0.713; χ(2) = 8.423, P = 0.204; χ(2) = 4.657, P = 0.540).

Conclusion: Segment or linear enhancement type is characterized by MR imaging. Early rim enhanced mass is ER/PR(-), Her2(-) breast cancer. The most important characteristics of MR imaging include a smooth edge of breast mass, very high intratumoral signal on fat suppression T2-weighted imaging and peripheral hyperintense pattern.

Download full-text PDF

Source

Publication Analysis

Top Keywords

her2- subtype
20
er/pr- her2-
20
breast cancer
16
subtype group
16
imaging
9
cancer subtypes
8
subtypes based
8
imaging findings
8
χ2
8
segment linear
8

Similar Publications

Purpose: This study aimed to conduct functional proteomics across breast cancer subtypes with bioinformatics analyses.

Methods: Candidate proteins were identified using nanoscale liquid chromatography with tandem mass spectrometry (NanoLC-MS/MS) from core needle biopsy samples of early stage (0-III) breast cancers, followed by external validation with public domain gene-expression datasets (TCGA TARGET GTEx and TCGA BRCA).

Results: Seventeen proteins demonstrated significantly differential expression and protein-protein interaction (PPI) found the strong networks including COL2A1, COL11A1, COL6A1, COL6A2, THBS1 and LUM.

View Article and Find Full Text PDF

Introduction Breast cancer (BC) is the most common malignancy among women worldwide and the leading cause of cancer-related mortality in women in Morocco. However, there is limited evidence on survival outcomes and treatment patterns among elderly patients with metastatic breast cancer (MBC) in this setting. Methods We conducted a retrospective cohort study at the Department of Medical Oncology, Hassan II University Hospital in Fez.

View Article and Find Full Text PDF

We present the case of a 45-year-old Caucasian woman diagnosed with synchronous bicentric breast cancer of differing molecular phenotypes in the same breast. The first tumor, an invasive ductal carcinoma (G1), was estrogen and progesterone receptor-positive and HER2-negative, with a low proliferative index (Ki67 10%). A second lesion, located in a different quadrant and appearing within weeks after biopsy, exhibited a triple-negative phenotype and a higher proliferative index (Ki67 30%).

View Article and Find Full Text PDF

Background The optimal surgical management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer with calcifications remains controversial, particularly when pathologic complete response (pCR) is suspected. Purpose To identify factors associated with pCR after neoadjuvant chemotherapy in patients with HER2-positive breast cancer and assess whether calcifications affect the performance of radiologic complete response (rCR) at MRI for predicting pCR. Materials and Methods This retrospective study included patients with HER2-positive breast cancer who received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab and underwent surgery between January 2021 and October 2023.

View Article and Find Full Text PDF

Sparking malignancy: nicotine as a driver of stemness and metastasis in triple-negative breast cancer.

J Pathol

September 2025

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, and remains one of the most aggressive and therapeutically challenging breast cancer subtypes, marked by early relapse, metastasis, and limited targeted treatment options. In a recent study published in The Journal of Pathology, Kuo et al provide compelling evidence that nicotine exposure, whether from tobacco smoke or e-cigarette vapor, drives TNBC progression by promoting stem-like and metastatic phenotypes. Integrating clinical datasets, patient tissues, cell lines, and in vivo models, the authors demonstrate that nicotine enhances tumor aggressiveness via coordinated upregulation of CHRNA9 and IGF1R.

View Article and Find Full Text PDF